These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 39186847)

  • 1. Large deletions and small insertions and deletions in the factor VIII gene predict unfavorable immune tolerance induction outcome in people with severe hemophilia A and high-responding inhibitors.
    Zuccherato LW; Souza RP; Camelo RM; Dias MM; Jardim LL; Santana MAP; Oliveira AG; Lorenzato CS; Cerqueira MH; Franco VKB; Ribeiro RA; Etto LY; Roberti MDRF; Callado FMA; de Cerqueira MAF; Pinto ISS; Garcia AA; Anegawa TH; Neves DCF; Tan DM; Tou RP; Chaves DG; van der Bom J; Rezende SM;
    Thromb Res; 2024 Oct; 242():109115. PubMed ID: 39186847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors.
    Coppola A; Margaglione M; Santagostino E; Rocino A; Grandone E; Mannucci PM; Di Minno G;
    J Thromb Haemost; 2009 Nov; 7(11):1809-15. PubMed ID: 19740093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune tolerance induction with recombinant factor VIII in hemophilia A patients with high responding inhibitors.
    Rocino A; Santagostino E; Mancuso ME; Mannucci PM
    Haematologica; 2006 Apr; 91(4):558-61. PubMed ID: 16585022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres.
    Nakar C; Manco-Johnson MJ; Lail A; Donfield S; Maahs J; Chong Y; Blades T; Shapiro A
    Haemophilia; 2015 May; 21(3):365-373. PubMed ID: 25581638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early immune tolerance induction is a unique predictor of favorable outcomes in hemophilia A children with intron 22 inversion and high-responding inhibitors.
    Sun J; Li Z; Li G; Liu G; Yao W; Zhen Y; Chen Z; Wu R
    Thromb Res; 2023 Jun; 226():56-60. PubMed ID: 37121012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement.
    Spena S; Garagiola I; Cannavò A; Mortarino M; Mannucci PM; Rosendaal FR; Peyvandi F;
    J Thromb Haemost; 2018 Apr; 16(4):778-790. PubMed ID: 29399993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W; Escuriola Ettingshausen C; Vdovin V; Zozulya N; Plyushch O; Svirin P; Andreeva T; Bubanská E; Campos M; Benedik-Dolničar M; Jiménez-Yuste V; Kitanovski L; Klukowska A; Momot A; Osmulskaya N; Prieto M; Šalek SZ; Velasco F; Pavlova A; Oldenburg J; Knaub S; Jansen M; Belyanskaya L; Walter O; ;
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Late immune tolerance induction in haemophilia A patients.
    Meeks SL; Chapman RL; Kempton C; Dunn AL
    Haemophilia; 2013 May; 19(3):445-8. PubMed ID: 23294063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
    Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
    Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study.
    Antun A; Monahan PE; Manco-Johnson MJ; Callaghan MU; Kanin M; Knoll C; Carpenter SL; Davis JA; Guerrera MF; Kruse-Jarres R; Ragni MV; Witmer C; McCracken CE; Kempton CL
    J Thromb Haemost; 2015 Nov; 13(11):1980-8. PubMed ID: 26382916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A possible mechanism for Inv22-related F8 large deletions in severe hemophilia A patients with high responding factor VIII inhibitors.
    Fujita J; Miyawaki Y; Suzuki A; Maki A; Okuyama E; Murata M; Takagi A; Murate T; Suzuki N; Matsushita T; Saito H; Kojima T
    J Thromb Haemost; 2012 Oct; 10(10):2099-107. PubMed ID: 22906111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F8 inversions of introns 22 and 1 confer a moderate risk of inhibitors in Mexican patients with severe hemophilia A. Concordance analysis and literature review.
    Luna-Záizar H; González-Alcázar JÁ; Evangelista-Castro N; Aguilar-López LB; Ruiz-Quezada SL; Beltrán-Miranda CP; Jaloma-Cruz AR
    Blood Cells Mol Dis; 2018 Jul; 71():45-52. PubMed ID: 29544691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study.
    van den Berg HM; Mancuso ME; Königs C; D'Oiron R; Platokouki H; Mikkelsen TS; Motwani J; Nolan B; Santagostino E;
    Thromb Haemost; 2020 Aug; 120(8):1166-1172. PubMed ID: 32572865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time between inhibitor detection and start of immune tolerance induction: Association with outcome in the BrazIT study.
    Camelo RM; Dias MM; Caram-Deelder C; Gouw S; de Magalhães LP; Zuccherato LW; Jardim LL; de Oliveira AG; de Albuquerque Ribeiro R; Franco VKB; do Rosário Ferraz Roberti M; de Araújo Callado FMR; Etto LY; de Cerqueira MAF; Cerqueira MH; Lorenzato CS; de Souza IS; Serafim ÉSS; Garcia AA; Anegawa TH; Neves DCF; Tan DM; van der Bom J; Rezende SM;
    J Thromb Haemost; 2022 Nov; 20(11):2526-2537. PubMed ID: 36102352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.
    Lapalud P; Rothschild C; Mathieu-Dupas E; Balicchi J; Gruel Y; Laune D; Molina F; Schved JF; Granier C; Lavigne-Lissalde G
    J Thromb Haemost; 2015 Apr; 13(4):540-7. PubMed ID: 25603934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spectrum of F8 Genotype and Genetic Impact on Inhibitor Development in Patients with Hemophilia A from Multicenter Cohort Studies (J-HIS) in Japan.
    Shinozawa K; Yada K; Kojima T; Nogami K; Taki M; Fukutake K; Yoshioka A; Shirahata A; Shima M;
    Thromb Haemost; 2021 May; 121(5):603-615. PubMed ID: 33254277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of seven novel mutations in the factor VIII gene in 18 unrelated Chinese patients with hemophilia A.
    Hua BL; Yan ZY; Liang Y; Yan M; Fan LK; Li KX; Xiao B; Liu JZ; Zhao YQ
    Chin Med J (Engl); 2010 Feb; 123(3):305-10. PubMed ID: 20193250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotolerance induction effectivity in hemophilia A children and neutralizing alloantibodies.
    Soto A V; Cortez S D; González S M
    Rev Chil Pediatr; 2020 Apr; 91(2):232-238. PubMed ID: 32730542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L; Pitlik E
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.